Williams Eloise, Low Soo Jen, Pollock Georgina L, Taouk Mona L, Prestedge Jacqueline, Howden Benjamin P, Chow Eric P F, Fairley Christopher K, Seib Kate L, McCarthy James S, Pasricha Shivani, Williamson Deborah A
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Lancet Microbe. 2025 Jul 10:101105. doi: 10.1016/j.lanmic.2025.101105.
Neisseria gonorrhoeae is a human pathogen of major public health importance due to its increasing global prevalence and antimicrobial resistance (AMR). Evidence suggests that oropharyngeal infection plays a key role in N gonorrhoeae transmission and AMR; however, our understanding of oropharyngeal gonorrhoea pathogenesis is poor. A controlled human infection model (CHIM) for oropharyngeal gonorrhoea will improve understanding of infection and accelerate urgently needed novel gonorrhoea prevention and therapeutic strategies. As the first step in the development of this CHIM, we describe a systematic approach to CHIM strain selection that leverages genomics and clinical data.
In this genomics-based analysis, we applied a systematic N gonorrhoeae challenge strain selection strategy incorporating genomic and clinical data to a primary dataset of clinical isolates of N gonorrhoeae collected from adult patients in Victoria, Australia, between Jan 1 and Dec 31, 2017, and July 1, 2019, and June 30, 2021. This selection strategy used clinical, phenotypic, and genomic characteristics to define a set of eight criteria that aimed to ensure the contemporary global clinical relevance of the candidate strains; select strains that would be applicable for the assessment of current and future gonorrhoea vaccines; and maximise participant safety by reducing the risk of disseminated gonococcal infection and clinically significant AMR. We applied these criteria to our primary dataset to generate a panel of potential challenge strains. From this final dataset of potential challenge strains, we predetermined that we would select up to ten isolates to proceed to the next stage of detailed phenotypic characterisation for final N gonorrhoeae CHIM strain selection.
5881 isolates comprised the primary dataset. After application of the selection criteria, most of the isolates (5795 [98·6%] of 5881) were excluded, mostly due to having clinically significant AMR and poor contemporary global clinical relevance. The remaining 86 N gonorrhoeae challenge strain candidates comprised five multilocus sequence types and six N gonorrhoeae multiantigen sequence types, many of which were represented by a single isolate. Of these 86 strains, five isolates were selected to maximise coverage of the phylogenetically distinct groups within the 86 candidate challenge strains and ensure representation of strains collected from various anatomical sites.
We transparently describe a novel, systematic, and rational genomics-based strategy for oropharyngeal gonorrhoea CHIM strain selection that improves the efficiency and transparency of CHIM strain selection and enables identification of contemporary and clinically relevant potential challenge strains. A final N gonorrhoeae challenge strain will be selected from the subset of five shortlisted candidates after detailed phenotypic assessment.
Medical Research Future Fund, Australian National Health and Medical Research Council and Australian Government Research Training Program.
淋病奈瑟菌是一种对公共卫生具有重大意义的人类病原体,因其在全球的流行率不断上升以及出现了抗菌药物耐药性(AMR)。有证据表明,口咽部感染在淋病奈瑟菌传播和AMR中起关键作用;然而,我们对口咽部淋病发病机制的了解甚少。口咽部淋病的受控人类感染模型(CHIM)将有助于增进对感染的理解,并加速迫切需要的新型淋病预防和治疗策略的研发。作为开发此CHIM的第一步,我们描述了一种利用基因组学和临床数据进行CHIM菌株选择的系统方法。
在这项基于基因组学的分析中,我们将一种结合了基因组和临床数据的系统性淋病奈瑟菌攻击菌株选择策略应用于2017年1月1日至12月31日、2019年7月1日至2021年6月30日期间从澳大利亚维多利亚州成年患者中收集的淋病奈瑟菌临床分离株的主要数据集。该选择策略利用临床、表型和基因组特征定义了一组八项标准,旨在确保候选菌株具有当代全球临床相关性;选择适用于评估当前和未来淋病疫苗的菌株;并通过降低播散性淋球菌感染风险和临床上显著的AMR风险来最大化参与者的安全性。我们将这些标准应用于主要数据集,以生成一组潜在的攻击菌株。从这个潜在攻击菌株的最终数据集中,我们预先确定将选择多达十个分离株进入下一阶段的详细表型特征分析,以最终选择淋病奈瑟菌CHIM菌株。
主要数据集包含5881个分离株。应用选择标准后,大多数分离株(5881个中的5795个[98.6%])被排除,主要原因是具有临床上显著的AMR且当代全球临床相关性较差。其余86个淋病奈瑟菌攻击菌株候选株包括五种多位点序列类型和六种淋病奈瑟菌多抗原序列类型,其中许多仅由单个分离株代表。在这86个菌株中,选择了五个分离株,以最大限度地覆盖86个候选攻击菌株中系统发育上不同的群体,并确保从不同解剖部位收集的菌株都有代表性。
我们透明地描述了一种新颖、系统且基于合理基因组学的口咽部淋病CHIM菌株选择策略,该策略提高了CHIM菌株选择的效率和透明度,并能够识别具有当代临床相关性的潜在攻击菌株。经过详细的表型评估后,将从五个入围候选株的子集中选出最终的淋病奈瑟菌攻击菌株。
医学研究未来基金、澳大利亚国家卫生与医学研究委员会和澳大利亚政府研究培训计划。